All News Incyte Corporation

Equities

INCY

US45337C1027

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-29 EDT			5-day change	1st Jan Change
52.56 ^USD	+1.70%		+1.23%	-16.29%

01:14pm	Earnings Flash (INCY) INCYTE Posts Q1 Revenue $880.9M, vs. Street Est of $924.6M	MT
01:11pm	Earnings Flash (INCY) INCYTE Posts Q1 EPS $0.64, vs. Street Est of $0.83	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (INCY) INCYTE Posts Q1 Revenue $880.9M, vs. Street Est of $924.6M	07:14am	MT
Earnings Flash (INCY) INCYTE Posts Q1 EPS $0.64, vs. Street Est of $0.83	07:11am	MT
Incyte: Q1 Earnings Snapshot	07:11am	AQ
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs	07:07am	BU
'Shadow Trading' Verdict A Reminder For Companies To Review Insider Trading Policies And Train Insiders	04-29	AQ
SEC Secures Groundbreaking Win In Shadow Trading Insider Trading Case	04-27	AQ
"Shadow Trading" Is Insider Trading: Jury Establishes Liability In Historic Shadow Trading Case	04-24	AQ
Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	04-24	MT
Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call	04-23
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists	04-23	BU
SEC Wins Novel 'Shadow Trading' Trial Against Biopharma Executive	04-22	AQ
Incyte Corporation entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.	04-22	CI
BMO Capital Adjusts Price Target on Incyte to $56 From $64	04-19	MT
Incyte to Report First Quarter Financial Results	04-11	BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - March 29, 2024	04-01	AQ
Incyte, China Medical System Sign Collaboration, License Agreement	04-01	MT
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	04-01	BU
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	04-01	CI
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03-29	BU
Trial of Insider Trading Case Against Former Medivation Employee Begins in California	03-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 10:00 am